| scholarly article | Q13442814 |
| P50 | author | Maria João Catalão | Q82606516 |
| Sérgio R. Filipe | Q37378762 | ||
| P2093 | author name string | Madalena Pimentel | |
| P2860 | cites work | Exploring the mycobacteriophage metaproteome: phage genomics as an educational platform | Q21563463 |
| Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosis. | Q41994445 | ||
| Growth inhibition of Mycobacterium smegmatis by mycobacteriophage-derived enzymes | Q42205265 | ||
| Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane | Q42373964 | ||
| Resuscitation-promoting factors are required for β-lactam tolerance and the permeability barrier in Mycobacterium tuberculosis. | Q42598704 | ||
| Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlmM and GlmU. | Q42731628 | ||
| Depletion of resuscitation-promoting factors has limited impact on the drug susceptibility of Mycobacterium tuberculosis | Q43027577 | ||
| Identification of hotspot regions of MurB oxidoreductase enzyme using homology modeling, molecular dynamics and molecular docking techniques | Q44324006 | ||
| The lytic cassette of mycobacteriophage Ms6 encodes an enzyme with lipolytic activity | Q44764387 | ||
| Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo | Q45044140 | ||
| Identification of the namH gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan | Q45136861 | ||
| β-Lactams against Tuberculosis--New Trick for an Old Dog? | Q46646582 | ||
| Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate | Q46978007 | ||
| Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases | Q47215437 | ||
| The Ms6 Mycolyl-Arabinogalactan Esterase LysB is Essential for an Efficient Mycobacteriophage-Induced Lysis. | Q47392080 | ||
| Treatment of Tuberculosis. | Q52987804 | ||
| Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. | Q53665765 | ||
| Effects of moenomycin on Escherichia coli. | Q54411026 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Inhibition studies on Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmU). | Q54698121 | ||
| WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update | Q56838263 | ||
| Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. | Q57456949 | ||
| 5-Benzylidenethiazolidin-4-ones as Multitarget Inhibitors of Bacterial Mur Ligases | Q58216000 | ||
| Fighting resistant tuberculosis with old compounds: the carbapenem paradigm | Q58346896 | ||
| Peptidoglycan precursor synthesis along the sidewall of pole-growing mycobacteria | Q58752773 | ||
| Mycobacteriophage Lysis Enzymes: Targeting the Mycobacterial Cell Envelope | Q58780325 | ||
| Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls | Q68556386 | ||
| Oldie but goodie: Repurposing penicillin for tuberculosis | Q85268364 | ||
| N-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of Mycobacterium tuberculosis | Q86827940 | ||
| The Envelope of Mycobacteria | Q22241995 | ||
| A new antibiotic kills pathogens without detectable resistance | Q24091299 | ||
| Crystal structures of two human pyrophosphorylase isoforms in complexes with UDPGlc(Gal)NAc: role of the alternatively spliced insert in the enzyme oligomeric assembly and active site architecture | Q24535935 | ||
| Muraymycin nucleoside-peptide antibiotics: uridine-derived natural products as lead structures for the development of novel antibacterial agents | Q26747275 | ||
| Rising to the challenge: new therapies for tuberculosis | Q27011672 | ||
| Mycobacteriophage Lysin B is a novel mycolylarabinogalactan esterase | Q27646315 | ||
| Structure and function of GlmU fromMycobacterium tuberculosis | Q27653924 | ||
| Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis | Q27653976 | ||
| Biochemical and Structural Characterization of Mycobacterium tuberculosis β-Lactamase with the Carbapenems Ertapenem and Doripenem | Q27660367 | ||
| Structure of the Mycobacterium tuberculosis d -Alanine: d -Alanine Ligase, a Target of the Antituberculosis Drug d -Cycloserine | Q27665159 | ||
| Targeting the Cell Wall of Mycobacterium tuberculosis: Structure and Mechanism of L,D-Transpeptidase 2 | Q27674732 | ||
| Penicillin-binding proteins and beta-lactam resistance | Q28267300 | ||
| Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine | Q28282522 | ||
| The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation | Q28486366 | ||
| Ancestral antibiotic resistance in Mycobacterium tuberculosis | Q28486382 | ||
| Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics | Q28487411 | ||
| Comparison of the UDP-N-acetylmuramate:L-alanine ligase enzymes from Mycobacterium tuberculosis and Mycobacterium leprae | Q28487429 | ||
| Peptidoglycan structure and architecture | Q29617858 | ||
| Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out. | Q30251606 | ||
| Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity | Q31473388 | ||
| Inhibition of Escherichia coli glycosyltransferase MurG and Mycobacterium tuberculosis Gal transferase by uridine-linked transition state mimics | Q33540441 | ||
| New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria | Q33600161 | ||
| Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to beta-lactam antibiotics. | Q33714602 | ||
| N Glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacterium spp. is altered by drug treatment | Q33716658 | ||
| Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem. | Q33730985 | ||
| The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. | Q33778121 | ||
| Non-classical transpeptidases yield insight into new antibacterials | Q33814192 | ||
| Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages | Q33847927 | ||
| A second endolysin gene is fully embedded in-frame with the lysA gene of mycobacteriophage Ms6. | Q33939117 | ||
| Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane | Q34169371 | ||
| Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis | Q34198711 | ||
| Mycobacteriophage endolysins: diverse and modular enzymes with multiple catalytic activities | Q34217656 | ||
| Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams | Q34229876 | ||
| Diversity in bacterial lysis systems: bacteriophages show the way. | Q34304410 | ||
| The mechanism of action of ramoplanin and enduracidin | Q34553065 | ||
| Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery | Q34645039 | ||
| Structure, biochemistry and mechanism of action of glycopeptide antibiotics | Q34665729 | ||
| Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors | Q35243846 | ||
| Wall teichoic acids of Staphylococcus aureus limit recognition by the drosophila peptidoglycan recognition protein-SA to promote pathogenicity. | Q35586976 | ||
| High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU. | Q35759365 | ||
| Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection | Q35860128 | ||
| Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. | Q36075809 | ||
| Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins | Q36171768 | ||
| Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility | Q36207233 | ||
| RodA as the missing glycosyltransferase in Bacillus subtilis and antibiotic discovery for the peptidoglycan polymerase pathway | Q36248543 | ||
| Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis | Q36310020 | ||
| Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development. | Q36319020 | ||
| MraY Inhibitors as Novel Antibacterial Agents | Q36321142 | ||
| In vitro antimycobacterial activities of capuramycin analogues | Q36424956 | ||
| Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. | Q36499160 | ||
| Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. | Q36844683 | ||
| Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis | Q37023233 | ||
| In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis | Q37026681 | ||
| Lcp1 Is a Phosphotransferase Responsible for Ligating Arabinogalactan to Peptidoglycan in Mycobacterium tuberculosis. | Q37168695 | ||
| Human NOD2 Recognizes Structurally Unique Muramyl Dipeptides from Mycobacterium leprae | Q37199844 | ||
| Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis | Q37247725 | ||
| Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide | Q37292790 | ||
| In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems | Q37335633 | ||
| Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis | Q37403156 | ||
| SEDS proteins are a widespread family of bacterial cell wall polymerases | Q37510553 | ||
| Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis | Q37519148 | ||
| Reinterpreting the mechanism of inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by D-cycloserine | Q37621626 | ||
| Bacterial autolysins trim cell surface peptidoglycan to prevent detection by the Drosophila innate immune system | Q37676985 | ||
| Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis | Q37681724 | ||
| Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams | Q37713160 | ||
| Bacterial cell wall assembly: still an attractive antibacterial target | Q37828273 | ||
| Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. | Q38111880 | ||
| Host-pathogen interactions during Mycobacterium tuberculosis infections | Q38123703 | ||
| Inhibitors of the peptidoglycan biosynthesis enzymes MurA-F. | Q38206339 | ||
| Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and menaquinone metabolic pathways? | Q38207733 | ||
| Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis | Q38232824 | ||
| The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan | Q38394431 | ||
| Genetics of Phage Lysis | Q38529842 | ||
| Genetics of Peptidoglycan Biosynthesis | Q38535745 | ||
| Assembly of the Mycobacterial Cell Wall | Q38612990 | ||
| UDP-GlcNAc pathway: Potential target for inhibitor discovery against M. tuberculosis | Q38675255 | ||
| Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target | Q38782638 | ||
| The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria | Q38973367 | ||
| Carbapenems against Mycobacterium tuberculosis: a review of the evidence | Q38989548 | ||
| Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis | Q39030679 | ||
| Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. | Q39038482 | ||
| Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. | Q39524371 | ||
| In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis | Q40187337 | ||
| Antimycobacterial Activities of Endolysins Derived From a Mycobacteriophage, BTCU-1. | Q40387314 | ||
| Impact of LytR-CpsA-Psr Proteins on Cell Wall Biosynthesis in Corynebacterium glutamicum. | Q40493671 | ||
| Loss of a Class A Penicillin-Binding Protein Alters β-Lactam Susceptibilities in Mycobacterium tuberculosis. | Q40541308 | ||
| Assembling of the Mycobacterium tuberculosis Cell Wall Core | Q40650968 | ||
| Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis | Q40675039 | ||
| Prevention of drug access to bacterial targets: permeability barriers and active efflux | Q40737334 | ||
| Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis. | Q41257101 | ||
| Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate | Q41329958 | ||
| Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis | Q41927847 | ||
| Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance | Q41991754 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell wall | Q128700 |
| peptidoglycan | Q206920 | ||
| tuberculosis | Q12204 | ||
| P304 | page(s) | 190 | |
| P577 | publication date | 2019-02-11 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis | |
| P478 | volume | 10 |
Search more.